Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2007

View Archived Issues

PARP inhibition may be beneficial in retinitis pigmentosa / News in Context

Latest findings reported for therapeutic agents under development for treatment of plaque psoriasis

Preclinical data on two novel PPAR modulators from Pierre Fabre

Inhibition of integrin alpha5beta1 may be useful in treating ocular neovascularization

Alizyme provides update on phase III programs

Novacea initiates phase II trial with AQ4N for ALL

BioCryst begins patient enrollment in pivotal forodesine trial

Threshold stops enrollment in phase II trial of glufosfamide

MedImmune and Crucell develop new antibodies for hospital-acquired bacterial infection

Neuron and Metabolic select NRP compound with therapeutic potential

Promising phase II data reported from ASA-404 phase II trial

Sanofi Pasteur and Institut Pasteur to codevelop malaria vaccine

AMDL seeks FDA approval for ELISA tumor marker test

Novel treatment option for drug addiction disclosed by State University of New York

Orexo to acquire Biolipox

Bristol-Myers Squibb licenses SARM program to Pharmacopeia

Disappointing phase II data reported for MEM-1003

Expansion cohort in phase I Hedgehog antagonist trial initiated by Genentech

FDA approves IND for CA9-SCAN pivotal phase III trial

FDA grants orphan drug status for tamibarotene in acute promyelocytic leukemia

Neuromed concludes SPA with FDA for a pivotal phase III NMED-1077 trial

Wyeth and Progenics initiate phase II oral methylnaltrexone trials

Pivotal phase III Zingo trial meets primary endpoint

Novel class I HDAC inhibitor developed at Merck & Co.

Recent patents disclose novel anxiolytic, antidepressant and antipsychotic agents

Only FDA-approved anthracycline extravasation kit reaches market

Study suggests feasibility of vaccine prevention of maternal CMV infection

Recent Bayer Schering Pharma patents report novel agents for male contraception

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...